Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Carteolol

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Carteolol
Clinical data
Trade namesOcupress
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa601078
License data
Routes of
administration
Eye drops
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability85%
MetabolismLiver, active with 8-hydrocarteolol
Eliminationhalf-life6–8 hours
ExcretionKidney (50–70%)
Identifiers
  • (RS)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC16H24N2O3
Molar mass292.379 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C2Nc1cccc(OCC(O)CNC(C)(C)C)c1CC2
  • InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) checkY
  • Key:LWAFSWPYPHEXKX-UHFFFAOYSA-N checkY
  (verify)

Carteolol is a non-selectivebeta blocker used to treatglaucoma. It is administered in the form ofeye drops.[citation needed]

Carteolol was patented in 1972 and approved for medical use in 1980.[1]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Carteolol is abeta blocker, or anantagonist of theβ-adrenergic receptors.[2] It isselective for theβ1-adrenergic receptor and hasintrinsic sympathomimetic activity.[2] Carteolol has also been found to act as aserotonin5-HT1A and5-HT1B receptorantagonist in addition to being a beta blocker.[3]

Pharmacokinetics

[edit]

Carteolol is classified as a beta blocker with lowlipophilicity and hence lower potential for crossing theblood–brain barrier.[2] This in turn may result in fewer effects in thecentral nervous system as well as a lower risk ofneuropsychiatric side effects.[2]

Chemistry

[edit]

The experimentallog P of carteolol is 1.1 and its predicted log P ranges from 0.99 to 2.39.[4][5][6][7] It is ahydrophilic or low-lipophilicity beta blocker.[7][2]

Society and culture

[edit]

Brand names

[edit]

Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.

References

[edit]
  1. ^Fischer J, Ganellin CR (2006).Analogue-based Drug Discovery. John Wiley & Sons. p. 460.ISBN 978-3-527-60749-5.
  2. ^abcdeCojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM (February 2021)."Neuropsychiatric Consequences of Lipophilic Beta-Blockers".Medicina (Kaunas).57 (2): 155.doi:10.3390/medicina57020155.PMC 7914867.PMID 33572109.
  3. ^Langlois M, Brémont B, Rousselle D, Gaudy F (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors".European Journal of Pharmacology.244 (1):77–87.doi:10.1016/0922-4106(93)90061-d.PMID 8093601.
  4. ^"Carteolol".PubChem. Retrieved10 July 2025.
  5. ^"C16H24N2O3".ChemSpider. 10 June 2024. Retrieved10 July 2025.
  6. ^"Carteolol: Uses, Interactions, Mechanism of Action".DrugBank Online. 19 September 2006. Retrieved10 July 2025.
  7. ^abMannhold R (February 2005). "The impact of lipophilicity in drug research: a case report on beta-blockers".Mini Rev Med Chem.5 (2):197–205.doi:10.2174/1389557053402701.PMID 15720289.

Further reading

[edit]
Drugs used forglaucoma preparations andmiosis (S01E)
Sympathomimetics
Parasympathomimetics
muscarinic
muscarinic/nicotinic
acetylcholinesterase inhibitors
Carbonic anhydrase inhibitors/
(sulfonamides)
Beta blocking agents
Prostaglandin analogues (F)
Other agents
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carteolol&oldid=1321392832"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp